Glenmark Pharmaceuticals Ltd. - Research Center
532296 GLENMARK Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
P&L
|
| More |
Profit loss account
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Income | |||||
| Operating income | 8,220.66 | 8,141.58 | 7,567.93 | 6,712.63 | 6,304.87 |
| Expenses | |||||
| Material consumed | 3,467.36 | 3,525.67 | 3,034.77 | 2,709.74 | 2,411.60 |
| Manufacturing expenses | 83.22 | 76.87 | 66.83 | 72.33 | 66.76 |
| Personnel expenses | 1,346.51 | 1,193.20 | 1,107.40 | 1,072.33 | 969.98 |
| Selling expenses | 353.06 | 323.50 | 240.87 | 318.06 | 357.72 |
| Adminstrative expenses | 1,497.76 | 1,334.13 | 1,227.73 | 1,235.94 | 1,171.34 |
| Expenses capitalised | - | - | - | - | - |
| Cost of sales | 6,747.90 | 6,453.36 | 5,677.59 | 5,408.40 | 4,977.39 |
| Operating profit | 1,472.77 | 1,688.22 | 1,890.34 | 1,304.23 | 1,327.48 |
| Other recurring income | 985.94 | 614.63 | 396.24 | 606.79 | 475.61 |
| Adjusted PBDIT | 2,458.71 | 2,302.85 | 2,286.58 | 1,911.02 | 1,803.09 |
| Financial expenses | 206.82 | 236.04 | 265.90 | 256.39 | 223.81 |
| Depreciation | 184.15 | 159.70 | 150.82 | 138.54 | 106.28 |
| Other write offs | - | - | - | - | - |
| Adjusted PBT | 2,067.74 | 1,907.11 | 1,869.87 | 1,516.09 | 1,473.00 |
| Tax charges | 363.11 | 339.66 | 294.31 | 180.10 | 329.88 |
| Adjusted PAT | 1,704.64 | 1,567.46 | 1,575.56 | 1,335.99 | 1,143.12 |
| Non recurring items | -495.24 | 431.94 | 76.38 | 13.13 | 475.46 |
| Other non cash adjustments | - | - | - | - | - |
| Reported net profit | 1,209.40 | 1,999.39 | 1,651.93 | 1,349.13 | 1,618.57 |
| Earnigs before appropriation | 16,073.36 | 14,921.25 | 12,992.40 | 11,408.51 | 10,127.41 |
| Equity dividend | 70.54 | 70.54 | 70.54 | 68.03 | 68.03 |
| Preference dividend | - | - | - | - | - |
| Dividend tax | - | - | - | - | - |
| Retained earnings | 16,002.82 | 14,850.71 | 12,921.86 | 11,340.47 | 10,059.38 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis